Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + carboplatin + trastuzumab + pertuzumab (Roche)
- Development stage
- Phase 3
- Lead developer
- Fudan University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A-Fudan University-breast cancer refers to Arm A of a Phase Ib/II Bayesian adaptive design umbrella study (FINEST/FASCINATE-N) conducted by Fudan University. This neoadjuvant regimen is specifically designed for patients with HER2-positive breast cancer. It consists of a chemotherapy backbone of paclitaxel (a microtubule-stabilizing agent) and carboplatin (a DNA-alkylating platinum agent), combined with dual HER2-targeted monoclonal antibodies: trastuzumab (Herceptin) and pertuzumab (Perjeta). Trastuzumab binds to domain IV of the HER2 extracellular domain to inhibit ligand-independent signaling and induce antibody-dependent cellular cytotoxicity (ADCC), while pertuzumab binds to domain II to prevent HER2 dimerization with other HER family members. This combination provides a comprehensive blockade of the HER2 pathway alongside synergistic cytotoxic effects to maximize pathological complete response (pCR) rates in the neoadjuvant setting.
- Other names
- Paclitaxel + Carboplatin + Trastuzumab + PertuzumabPCH+HP
02
Targets
DNAHER2 ECD subdomain II (Human epidermal growth factor receptor 2 dimerization interface)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on paclitaxel + carboplatin + trastuzumab + pertuzumab (Roche).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + carboplatin + trastuzumab + pertuzumab (Roche).